| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5505100 | Biochemical and Biophysical Research Communications | 2017 | 26 Pages |
Abstract
Treatment with RLX in mice after MI reduces susceptibility to AF due to anti-inflammatory and anti-fibrotic properties. Because to these favorable actions, RLX may become a new therapeutic option in the treatment of AF, even when complicating MI.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Thomas Beiert, Vedat Tiyerili, Vincent Knappe, Verena Effelsberg, Markus Linhart, Florian Stöckigt, Sabine Klein, Robert Schierwagen, Jonel Trebicka, Georg Nickenig, Jan W. Schrickel, René P. Andrié,